ORKA today
$105.70-$1.47 (-1.37%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourExpanding
1 hourLeaning Bullish
15 minBearish
5 minBearish
Daily trend turns up above $82.95
Key levels
Resistance$115.52
Resistance$105.84
Support$98.29
Support$88.83
Latest news & SEC filings
EarningsOruka Therapeutics Posts Q3 2026 Results, Gives Business Update
EarningsOruka Therapeutics posts wider Q3 loss than analysts forecast
All ORKA news →About Oruka Therapeutics
Oruka Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal antibody treatments for psoriasis and other inflammatory and immunology conditions. Its lead candidates are ORKA-001, aimed at a protein involved in immune signaling, and ORKA-002, aimed at two related inflammatory targets, with a third undisclosed program also in development. The company operates in the United States and licenses related antibody technology from Paragon Therapeutics.
Based on the company's 10-K filed Mar 12, 2026.
Nasdaq · Healthcare
Oruka Therapeutics, Inc. (ORKA)
What Is the Price Target for ORKA?
SEPT Low Target
$85.00
SEPT Mid Target
$127.50
SEPT High Target
$160.00
Analyst Consensus
$127.50
Is ORKA a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ORKA.
Start Free Trial →Is ORKA Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$127.50
12
Moat Score
NONE
1/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with ORKA?
Insider Signal
SELLING
0 buys / 16 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Quinlan Paul T | officer | Buy | 9,000 | $70K | Oct 20, 2026 |
| Quinlan Paul T | officer | Sale | 400 | $30K | Oct 20, 2026 |
| Quinlan Paul T | officer | Sale | 500 | $38K | Oct 20, 2026 |
| Quinlan Paul T | officer | Sale | 1,000 | $77K | Oct 20, 2026 |
| Quinlan Paul T | officer | Sale | 4,100 | $323K | Oct 20, 2026 |
| Quinlan Paul T | officer | Sale | 3,000 | $238K | Oct 20, 2026 |
| Goncalves Joana | officer | Buy | 3,500 | $24K | Oct 15, 2026 |
| Goncalves Joana | officer | Sale | 2,853 | $211K | Oct 15, 2026 |
| Goncalves Joana | officer | Sale | 1,847 | $138K | Oct 15, 2026 |
| Goncalves Joana | officer | Sale | 1,400 | $106K | Oct 15, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ORKA Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
N/A
FCF Growth YoY
-370.2%
Revenue Trend
UNKNOWN
Dark Pool Trades for ORKA
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ORKA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 17:58:46 | $105.38 | 4,769 | $$503K | SELL |
| 16:48:17 | $107.00 | 1,600 | $$171K | BUY |
| 16:47:56 | $106.84 | 1,100 | $$118K | BUY |
| 16:33:29 | $105.89 | 1,100 | $$116K | MIDPOINT |
| 16:26:09 | $105.53 | 10,000 | $$1.1M | MIDPOINT |
5 dark pool trades shown · $$2.0M preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for ORKA
PREVIEWSEPT Investing provides real-time options flow tracking for ORKA, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $105 | Nov 20 | 8 | $$560 | 1 | SWEEP |
| CALL | $105 | Nov 20 | 8 | $$2800 | 5 | SWEEP |
| CALL | $105 | Nov 20 | 8 | $$1120 | 2 | SWEEP |
| CALL | $105 | Nov 20 | 8 | $$560 | 1 | SWEEP |
| CALL | $105 | Nov 20 | 8 | $$560 | 1 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About ORKA
2 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for ORKA. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
SEPT Brain on $ORKA -- Bearish U.S. Central Command Posts On X "U.S. Forces Carried Out Self Defense Strikes Against Iranian Military Facilities Including Missile And Drone Launch Strikes; U.S. Milit...
Zone Setup -- $ORKA (Oruka Therapeutics, Inc.) Price: $85.21 | Zone: $82.22 to $91.78 Conviction: HIGH | Analyst upside: +45.2% Major volume event today — setup forming. Strong positive news (3+ vs ...
Join 3,500+ traders discussing ORKA in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Oruka Therapeutics, Inc. (ORKA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ORKA — frequently asked questions
What is ORKA stock price today?
Oruka Therapeutics, Inc. (ORKA) is at $105.70, down 1.37% (-$1.47) at the Nov 12, 2026 close.
Why is ORKA stock moving today?
Latest ORKA news — Nov 9, 2026: Oruka Therapeutics Posts Q3 2026 Results, Gives Business Update · Nov 9, 2026: Oruka Therapeutics posts wider Q3 loss than analysts forecast
Why did ORKA stock move on Oct 26, 2026?
Oruka Therapeutics shares surged 10.32% to close at $90.44 after the company reported positive week 16 data for its experimental biologic ORKA-001 in the EVERLAST-B psoriasis trial. The mid-stage study showed 61% of patients achieved PASI 100 (clear or almost clear skin) and 86% reached PASI 90, with the drug beating placebo and remaining on track for late-stage testing in the first half of 2027.
What is the ORKA price target?
The average analyst price target for ORKA is $127.50, ranging from $85 to $160, based on 8 analysts.
What do analysts rate ORKA?
Analyst ratings for ORKA: 13 Buy, 0 Hold, 0 Sell — consensus Strong Buy.
Did ORKA beat earnings?
ORKA last reported on Aug 10, 2026: EPS -$0.55 vs -$0.51 expected — a miss of 7.3%.
Does ORKA pay a dividend?
ORKA does not currently pay a dividend.
What are ORKA support and resistance levels?
Support: $98.29, $88.83, $82.95. Resistance: $105.84, $115.52, $138.24.
What are insiders doing with ORKA?
Insider activity: SELLING, 0 buys and 16 sells in the last 90 days.
What is the latest news on ORKA?
Nov 9, 2026: Oruka Therapeutics Posts Q3 2026 Results, Gives Business Update · Nov 9, 2026: Oruka Therapeutics posts wider Q3 loss than analysts forecast